Skip to main content
TransThera Sciences (Nanjing), Inc. logo

TransThera Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 2617 ISIN · CNE100006T02 HKEX Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2026-04-21 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 2617

About TransThera Sciences (Nanjing), Inc.

https://www.transthera.com

TransThera Sciences (Nanjing), Inc. is a clinical-stage, R&D-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapies. Established in 2014, the company employs a clinical demand-oriented approach to address diseases with significant unmet medical needs. TransThera's pipeline is dedicated to generating first-in-class, best-in-class, and highly differentiated treatments, primarily targeting therapeutic areas such as oncology, inflammatory diseases, and cardiovascular conditions.

Recent filings

Filing Released Lang Actions
COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement from TransThera Sciences (Nanjing), Inc. regarding the completion of a placing of new H shares under the general mandate. It details the number of shares placed, the placing price, use of proceeds, and the shareholding structure before and after the placing. The content focuses on fundraising and capital structure changes, specifically the issuance of new shares and allocation of proceeds. There is no indication that this is a full financial report, audit, or earnings release. The document is not a proxy solicitation, voting result, or management change announcement. It is a capital/financing update about a share placing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6769 characters) and detailed financial figures support this classification with high confidence.
2026-04-21 English
VOLUNTARY ANNOUNCEMENT TransThera Sciences (Nanjing), Inc. Presented Lineage Reprogramming as a Resistance Mechanism to Endocrine Therapy in HR+ Breast Cancer, as Well as Preclinical Data for Tiangoti
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by TransThera Sciences (Nanjing), Inc. regarding a scientific poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. It discusses research findings and clinical trial updates related to a drug candidate, Tinengotinib. The document is relatively short (4206 characters) and serves to inform shareholders and investors about recent business advancements and scientific presentations. It does not contain financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. It is not a report publication announcement since it does not mention the release or availability of a formal report. The content is primarily an update on scientific and clinical progress, which fits best under a general regulatory announcement category rather than a specific financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-04-21 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN CONFIRMATORY PHASE III CLINICAL TRIAL OF TINENGOTINIB MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by TransThera Sciences (Nanjing), Inc. regarding the dosing of the first patient in a Phase III clinical trial for a drug candidate. It provides business and clinical trial updates but does not contain financial statements, regulatory certifications, or detailed financial data. The document is relatively short (3877 characters) and serves as a business progress update rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention the release or availability of a report. The content is an operational update about clinical trial progress, which is typically classified as a general regulatory announcement or miscellaneous company update. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2026-04-17 English
PLACING OF NEW H SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 90% confidence The document is a Hong Kong Stock Exchange announcement by TransThera Sciences regarding the conditional placing (issuance) of 5,085,000 new H Shares under the Company’s existing general mandate. It provides details of the placing agreement, share numbers, pricing, conditions, use of proceeds, and related equity fund raising activity. This is a classic share issuance/capital change announcement, fitting the “Share Issue/Capital Change” category.
2026-04-15 English
PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME
Regulatory Filings Classification · 85% confidence The document is a Hong Kong Stock Exchange announcement of the board’s resolution to propose adoption of an H Share Award Scheme and to convene an extraordinary general meeting. It is not the actual share scheme rules or grant document, nor is it a circular or proxy statement (PSI) requesting votes – the circular will follow. It is also not a financial report, earnings release, dividend notice or share issue notice in the strict sense; rather, it is a regulatory announcement under the Listing Rules. Therefore, it falls into the fallback category “Regulatory Filings” (RNS).
2026-04-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 88% confidence The document is an HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Exchange Listing Rules, detailing movements in authorized/issued share capital, public float sufficiency confirmations, and confirmations of compliance. It is a routine regulatory submission to the exchange, not an earnings release, management commentary, dividend notice, or standalone financial report. It does not announce a specific new share issuance or capital raising event (so it is not SHA), but rather is a periodic compliance filing under listing rules. Therefore it falls under the fallback category “Regulatory Filings” (Code: RNS).
2026-04-02 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.